Q3 FY2026
Filed Nov 9, 2026Bicara reports Q3 2026 net loss of $71.2 million as R&D and G&A spending rises; FORTIFI-HN01 pivotal trial enrollment substantially achieved
The filing shows clear clinical execution, with substantial enrollment in the FORTIFI-HN01 pivotal trial and an interim readout planned for mid-2027. Operating costs rose sharply versus the prior-year quarter, and the company reports no revenue, so the net loss widened. Cash and marketable securities of $442.3 million are reported as funding operations into the first half of 2029.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026GAAP | $56.48M | – | – |
| General and administrative expenses, Q3 2026GAAP | $19.23M | – | – |
| Total operating expenses, Q3 2026GAAP | $75.71M | – | – |
| Loss from operations, Q3 2026GAAP | −$75.71M | – | – |
| Interest income, Q3 2026GAAP | $4.52M | – | – |
| Net loss before income taxes, Q3 2026GAAP | −$71.19M | – | – |
| Income tax expense, Q3 2026GAAP | −$54K | – | – |
| Net loss, Q3 2026GAAP | −$71.25M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(1.04) | – | – |
| Total comprehensive loss, Q3 2026GAAP | −$72.55M | – | – |
| Total stock-based compensation expense, Q3 2026GAAP | $9.98M | – | – |
| Research and development expenses, nine months 2026GAAP | $149.7M | – | – |
| General and administrative expenses, nine months 2026GAAP | $46.19M | – | – |
| Total operating expenses, nine months 2026GAAP | $195.9M | – | – |
| Loss from operations, nine months 2026GAAP | −$195.9M | – | – |
| Interest income, nine months 2026GAAP | $13.18M | – | – |
| Net loss before income taxes, nine months 2026GAAP | −$182.7M | – | – |
| Income tax expense, nine months 2026GAAP | −$168K | – | – |
| Net loss, nine months 2026GAAP | −$182.9M | – | – |
| Net loss per share, basic and diluted, nine months 2026GAAP | $(2.78) | – | – |
| Total comprehensive loss, nine months 2026GAAP | −$185.0M | – | – |
| Total stock-based compensation expense, nine months 2026GAAP | $24.08M | – | – |
| Cash, cash equivalents and marketable securities, as of Sept 30, 2026other | $442.3M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Weighted-average shares outstanding rose to 68,375,411 for Q3 2026 from 54,563,864 for Q3 2025 (as printed in the statement of operations).
What drove it
- Company explanation for the R&D increase: primarily costs associated with the ongoing FORTIFI-HN01 pivotal trial, FORTIFI-FLEX trial, Phase 1/1b dose expansion cohorts, and an increase in personnel costs.
- Company explanation for the G&A increase: primarily additional personnel costs and professional fees associated with expanding the organization as the company advances its pivotal trial and prepares for potential commercialization.
- Stock-based compensation expense in the quarter was $9,980 thousand, against $3,614 thousand in Q3 2025, as printed in the statement of operations footnote.
Concerns
- Total operating expenses for Q3 2026 were $75,711 thousand against $40,676 thousand in Q3 2025, and the net loss widened to $(71,249) thousand from $(36,330) thousand.
- The company reports no revenue in the filing, so the operating loss is not offset by product or licensing income.
- Accrued expenses and other current liabilities rose to $46,184 thousand from $18,898 thousand at December 31, 2025.
- The company states it will need a commercial organization ready for a potential U.S. approval, and the filing names the need for additional funds to commercialize ficerafusp alfa as a risk factor.
What to watch
- Topline results from the interim analysis of the FORTIFI-HN01 pivotal trial, expected in mid-2027.
- FORTIFI-FLEX results (loading dose of 1500mg QW followed by 2250mg Q3W versus 1500mg QW), which the company expects by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.
- Phase 1b expansion cohort data in 3L+ mCRC (RAS/BRAF wild type MSS), to be presented in January 2027.
- Preclinical data on tumor-targeted TGF-β neutralization at ESMO Immuno-Oncology & Advanced Therapies Congress 2026, December 14-16 in London.
- Quarterly trend in R&D and G&A spend as the pivotal trial and commercial preparation continue.
- Cash runway into the first half of 2029 as stated by the company.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $442.3 million as of September 30, 2026, compared with $414.8 million as of December 31, 2025, as stated in the release.
- Balance sheet at September 30, 2026: cash and cash equivalents $82,021 thousand (December 31, 2025: $96,685 thousand); marketable securities $360,325 thousand (December 31, 2025: $318,116 thousand).
- Total assets were $460,642 thousand at September 30, 2026, compared with $430,994 thousand at December 31, 2025.
- Total liabilities were $51,231 thousand at September 30, 2026, compared with $29,542 thousand at December 31, 2025.
- Total stockholders' equity was $409,411 thousand at September 30, 2026, compared with $401,452 thousand at December 31, 2025.
- Accrued expenses and other current liabilities were $46,184 thousand at September 30, 2026, compared with $18,898 thousand at December 31, 2025.
- The company expects existing cash, cash equivalents and marketable securities to fund operations into the first half of 2029, based on current operating and development plans.
Analysis
Bicara's third quarter 2026 release is a pre-revenue update. The company reports no revenue or gross margin line. Its results are driven by operating expenses, which were $75,711 thousand in Q3 2026 against $40,676 thousand in Q3 2025. Research and development expense was $56,476 thousand (against $32,975 thousand) and general and administrative expense was $19,235 thousand (against $7,701 thousand). The company attributes the R&D increase to the FORTIFI-HN01 pivotal trial, the FORTIFI-FLEX trial, Phase 1/1b dose expansion cohorts and personnel costs, and attributes the G&A increase to personnel and professional fees tied to pivotal trial progress and commercial preparation.
The net loss for the quarter was $(71,249) thousand, or $(1.04) per share, compared with $(36,330) thousand, or $(0.67) per share, a year earlier. Interest income of $4,516 thousand (against $4,386 thousand) only partly offsets the operating cost increase. For the nine months, operating expenses were $195,903 thousand (against $114,482 thousand) and the net loss was $(182,896) thousand, or $(2.78) per share, against $(100,564) thousand, or $(1.84) per share.
On the business side, the company says it achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line recurrent or metastatic HPV-negative HNSCC, enabling topline interim results in mid-2027. It is also enrolling FORTIFI-FLEX, which it expects will report results by the time of a potential U.S. approval. The filing does not give any sales or commercial guidance and no outlook figures are provided.
On the balance sheet, cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, against $414.8 million at December 31, 2025. Total liabilities rose to $51,231 thousand from $29,542 thousand, mainly reflecting the accrued expenses line, which the filing shows at $46,184 thousand against $18,898 thousand. Stockholders' equity was $409,411 thousand against $401,452 thousand. The company states its cash will fund operations into the first half of 2029.
The read is that clinical and enrollment milestones were met in the quarter, while the cost base and net loss rose sharply year on year. The filing does not provide a cash flow statement, so operating or free cash flow cannot be read from this release.
Management, verbatim
Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need,
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
With our commercial leadership team now in place, we are well-positioned as we continue to prepare to bring ficerafusp alfa to patients.
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
Not in the filing
stated, not guessed- No cash flow statement, so operating cash flow, investing cash flow and free cash flow are not available.
- No year-over-year or quarter-over-quarter percentage changes are printed for any line item.
- No Q2 2026 comparative figures are printed, so sequential changes are not available.
- No segment or revenue breakdown is reported; the company reports no revenue line.
- No gross margin figure is reported.
- No prior-period outlook was provided, so no comparison against guidance is possible.
- No financial guidance for 2026 or later periods is printed.
- No share repurchase, dividend or other capital return activity is reported.
- No consensus estimates or analyst expectations are present in the filing.
- No share price reaction is present in the filing.
- Prior-year comparative balance sheet figures are shown as of December 31, 2025, not as a prior-year quarter, so they are placed in the balance sheet section rather than in prior_year fields.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.